These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 20368570

  • 1. High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Kyriakou C, Canals C, Sibon D, Cahn JY, Kazmi M, Arcese W, Kolbe K, Gorin NC, Thomson K, Milpied N, Niederwieser D, Indrák K, Corradini P, Sureda A, Schmitz N.
    J Clin Oncol; 2010 May 01; 28(13):2227-32. PubMed ID: 20368570
    [Abstract] [Full Text] [Related]

  • 2. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia.
    Anagnostopoulos A, Hari PN, Pérez WS, Ballen K, Bashey A, Bredeson CN, Freytes CO, Gale RP, Gertz MA, Gibson J, Goldschmidt H, Lazarus HM, McCarthy PL, Reece DE, Vesole DH, Giralt SA.
    Biol Blood Marrow Transplant; 2006 Aug 01; 12(8):845-54. PubMed ID: 16864055
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS, Kim K, Cheong JW, Min YH, Suh C, Kim H, Jo DY, Ryoo HM, Yoon SS, Lee JH, Korean Multiple Myeloma Working Party.
    Biol Blood Marrow Transplant; 2009 Apr 01; 15(4):463-70. PubMed ID: 19285634
    [Abstract] [Full Text] [Related]

  • 5. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J, Shepherd JD, Sutherland HJ, Nevill TJ, Nitta J, Le A, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Toze CL, Smith CA, Barnett MJ, Song KW.
    Biol Blood Marrow Transplant; 2007 Aug 01; 13(8):925-31. PubMed ID: 17640596
    [Abstract] [Full Text] [Related]

  • 6. Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant.
    Cheema PK, Zadeh S, Kukreti V, Reece D, Chen C, Trudel S, Mikhael J.
    Biol Blood Marrow Transplant; 2009 Jun 01; 15(6):686-93. PubMed ID: 19450753
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre.
    Perz JB, Giles C, Szydlo R, O'Shea D, Sanz J, Chaidos A, Wagner S, Davis J, Loaiza S, Marin D, Apperley J, Olavarria E, Rahemtulla A, Lampert I, Naresh K, Samson D, MacDonald D, Kanfer EJ.
    Bone Marrow Transplant; 2007 Jan 01; 39(1):41-7. PubMed ID: 17115062
    [Abstract] [Full Text] [Related]

  • 10. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma.
    Majhail NS, Weisdorf DJ, Defor TE, Miller JS, McGlave PB, Slungaard A, Arora M, Ramsay NK, Orchard PJ, MacMillan ML, Burns LJ.
    Biol Blood Marrow Transplant; 2006 Oct 01; 12(10):1065-72. PubMed ID: 17084370
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.
    d'Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, Holte H, Österborg A, Merup M, Brown P, Kuittinen O, Erlanson M, Østenstad B, Fagerli UM, Gadeberg OV, Sundström C, Delabie J, Ralfkiaer E, Vornanen M, Toldbod HE.
    J Clin Oncol; 2012 Sep 01; 30(25):3093-9. PubMed ID: 22851556
    [Abstract] [Full Text] [Related]

  • 13. Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma?
    Al-Faris N, Al Harbi T, Goia C, Pappo A, Doyle J, Gassas A.
    Pediatr Blood Cancer; 2007 Aug 01; 49(2):190-5. PubMed ID: 17262797
    [Abstract] [Full Text] [Related]

  • 14. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
    Sirvent A, Dhedin N, Michallet M, Mounier N, Faucher C, Yakoub-Agha I, Mohty M, Robin M, Tabrizi R, Clement L, Bilger K, Larosa F, Contentin N, Huyn A, François S, Bulabois CE, Ceballos P, Bourrhis JH, Buzyn A, Cornillon J, Guillerm G, de Revel T, Bay JO, Guilhot F, Milpied N.
    Biol Blood Marrow Transplant; 2010 Jan 01; 16(1):78-85. PubMed ID: 19744569
    [Abstract] [Full Text] [Related]

  • 15. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT).
    Björkstrand B, Svensson H, Goldschmidt H, Ljungman P, Apperley J, Mandelli F, Marcus R, Boogaerts M, Alegre A, Remes K, Cornelissen JJ, Bladé J, Lenhoff S, Iriondo A, Carlson K, Volin L, Littlewood T, Goldstone AH, San Miguel J, Schattenberg A, Gahrton G.
    Bone Marrow Transplant; 2001 Mar 01; 27(5):511-5. PubMed ID: 11313685
    [Abstract] [Full Text] [Related]

  • 16. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
    Arranz R, Conde E, Grande C, Mateos MV, Gandarillas M, Albo C, Lahuerta JJ, Fernández-Rañada JM, Hernández MT, Alonso N, García Vela JA, Garzón S, Rodríguez J, Caballero D, Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL-TAMO).
    Eur J Haematol; 2008 Mar 01; 80(3):227-35. PubMed ID: 18088400
    [Abstract] [Full Text] [Related]

  • 17. Estimating late adverse events using competing risks after autologous stem-cell transplantation in aggressive non-Hodgkin lymphoma patients.
    Ruiz-Soto R, Sergent G, Gisselbrecht C, Larghero J, Ertault M, Hennequin C, Manson J, de Kerviler E, Briere J, Mounier N.
    Cancer; 2005 Dec 15; 104(12):2735-42. PubMed ID: 16284986
    [Abstract] [Full Text] [Related]

  • 18. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience.
    Rodriguez J, Caballero MD, Gutierrez A, Gandarillas M, Sierra J, Lopez-Guillermo A, Sureda A, Zuazu J, Marin J, Arranz R, Carreras E, Leon A, De Sevilla AF, San Miguel JF, Conde E, GEL/TAMO Spanish Group.
    Haematologica; 2003 Dec 15; 88(12):1372-7. PubMed ID: 14687990
    [Abstract] [Full Text] [Related]

  • 19. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle.
    Brice P, Bouabdallah R, Moreau P, Divine M, André M, Aoudjane M, Fleury J, Anglaret B, Baruchel A, Sensebe L, Colombat P.
    Bone Marrow Transplant; 1997 Jul 15; 20(1):21-6. PubMed ID: 9232251
    [Abstract] [Full Text] [Related]

  • 20. Autologous stem cell transplantation in patients with chronic lymphocytic leukaemia: the Finnish experience.
    Jantunen E, Itälä M, Siitonen T, Juvonen E, Koivunen E, Koistinen P, Volin L, Remes K, Nousiainen T.
    Bone Marrow Transplant; 2006 Jun 15; 37(12):1093-8. PubMed ID: 16699533
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.